Váncsa, Andrea and Gergely, Lajos and Ponyi, Andrea and Lakos, Gabriella and Nemeth, Júlia and Dankó, Katalin (2010) Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. JOINT BONE SPINE, 77 (2). pp. 125-130. ISSN 1297-319X
|
Text
1_s2.0_S1297319X10000114_main_u.pdf Restricted to Repository staff only Download (223kB) | Request a copy |
Abstract
OBJECTIVE: The current study was performed in order to determine the prevalence of different myositis-specific and myositis-associated antibodies, as well as their association with clinical characteristics, disease course and response to therapy in 169 Hungarian patients with idiopathic inflammatory myopathy. METHODS: Sera of 130 primary and 39 overlap myositis including systemic sclerosis (13), rheumatoid arthritis (12), systemic lupus erythematosus (5) and Sjogren's syndrome (9) cases were analyzed. Antinuclear antibody, scleroderma-associated antibodies (anti-centromere, anti-topoisomerase I), anti-Jo-1, anti-PL-7, anti-PL-12, anti-Mi-2, anti-SRP and anti-PM-Scl, anti-Ku, anti-SS-A, anti-SS-B, anti-U1snRNP were tested. Autoantibody results were compared with clinical characteristics, disease course of overlap versus primary myositis patients, as well as with response to therapy. RESULTS: Associated connective tissue disease occurred in 23.1% of the patients. Myositis-associated antibodies were found in 8.5% of primary myositis patients, indicating that 11 additional primary myositis patients (23% vs. 29.6%) can be classified as overlap in all cohort according to the newly proposed diagnostic criteria. Polymyositis was found to be the most common myositis form in overlap myositis (87.2%), while scleroderma was the most common disease associated (33.3%). ANA was positive in 25.4% of primary and in 61.5% of overlap myositis cases. Altogether 39.6% of myositis patients (n=67) had autoantibodies, most commonly anti Jo-1 (18.3%) correlating with a polycyclic disease course. CONCLUSION: Inclusion of myositis-specific and associated antibodies into the newly proposed diagnostic criteria for inflammatory myopathies is of great importance in order to determine subclasses and to introduce adequate therapy in time.
| Item Type: | Article |
|---|---|
| Additional Information: | CI: Copyright 2010 Societe francaise de rhumatologie. Published by Elsevier SAS. All : rights reserved. |
| Uncontrolled Keywords: | Young Adult; Treatment Outcome; Seroepidemiologic Studies; Retrospective Studies; Polymyositis/*classification/drug therapy/epidemiology/*immunology; Middle Aged; Male; Immunosuppressive Agents/therapeutic use; Humans; Follow-Up Studies; Female; Dermatomyositis/*classification/drug therapy/epidemiology/*immunology; Cross-Sectional Studies; Autoantibodies/blood/*immunology; Aged; Adult; Adolescent; egyetemen (Magyarországon) készült közlemény |
| Subjects: | R Medicine / orvostudomány > R1 Medicine (General) / orvostudomány általában |
| SWORD Depositor: | MTMT SWORD |
| Depositing User: | MTMT SWORD |
| Date Deposited: | 05 Apr 2017 12:01 |
| Last Modified: | 05 Apr 2017 12:01 |
| URI: | http://real.mtak.hu/id/eprint/50978 |
Actions (login required)
![]() |
Edit Item |




